Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drug-drug Interaction Study of the Effect of Omeprazole 80 mg q.d. at Steady State on the Pharmacokinetics and Pharmacodynamics of Aggrenox Every 12 Hours at Steady State in Healthy Male and Female Volunteers (an Open-label, Randomised, Crossover Study).

Next Previous
Trial Profile

Drug-drug Interaction Study of the Effect of Omeprazole 80 mg q.d. at Steady State on the Pharmacokinetics and Pharmacodynamics of Aggrenox Every 12 Hours at Steady State in Healthy Male and Female Volunteers (an Open-label, Randomised, Crossover Study).

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin/dipyridamole (Primary) ; Omeprazole
  • Indications Duodenal ulcer; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Peptic ulcer; Stroke; Thrombosis; Transient ischaemic attacks
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 03 Feb 2012 Results have been presented at the 2012 International Stroke Conference according to a Boehringer Ingelheim media release. Results were also reported in the media release.
  • 05 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 07 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top